Artificial intelligence company Anthropic has confirmed the launch of a physical wet lab in the San Francisco Bay Area, taking its life-sciences ambitions beyond software modeling and into hands-on biological experimentation. Eric Kauderer-Abrams, Anthropic’s head of life sciences, told Reuters the facility is already operational and that real lab work remains essential to testing biology.
The new lab is not exclusively focused on drug discovery, according to a company spokesperson, but it supports broader early-stage research into diseases that traditional pharmaceutical companies have largely ignored because of limited financial incentives. Kauderer-Abrams said Anthropic is interested in complex therapeutic areas, potentially including bispecific and trispecific antibodies, although the company has not disclosed a specific disease target or drug candidate.
Anthropic has been rapidly expanding its life-sciences operations. It acquired startup Coefficient Bio for about $400 million in stock, added Novartis CEO Vas Narasimhan to its board, and launched Claude Science, a research workbench connected to more than 60 scientific databases covering genomics, proteomics and structural biology. The company is also working with major pharmaceutical firms, including Genentech, Bristol Myers Squibb and Novo Nordisk.
In August, Anthropic introduced a Model Hardware Standard to help AI systems communicate with lab equipment. The company is exploring whether its Claude models can direct robotic systems to run experiments with minimal staffing, though Kauderer-Abrams said the effort remains in the “very early innings” and that human oversight is still required.
The expansion comes during a period of intense ambition and internal caution at Anthropic. CEO Dario Amodei has written that his father died of a disease shortly before a cure was found, giving the work personal significance. The company is also preparing for a potential IPO that could value it at around $2 trillion, even as some researchers warn about advanced AI risks, including possible misuse in biological weapons development.
Rival Alphabet’s Isomorphic Labs has been pursuing clinical drug trials and recently delayed that goal to the end of 2026. Anthropic says it does not plan to run clinical trials or bring drugs to market, positioning itself as a research partner rather than a direct competitor to pharmaceutical companies.
